

BioScrip, Inc.  
Form 4/A  
August 26, 2015

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
See Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Coliseum Capital Management, LLC

(Last) (First) (Middle)

METRO CENTER, 1 STATION  
PLACE, 7TH FLOOR SOUTH

(Street)

STAMFORD, CT 06902

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading  
Symbol

BioScrip, Inc. [BIOS]

3. Date of Earliest Transaction  
(Month/Day/Year)

08/21/2015

4. If Amendment, Date Original  
Filed(Month/Day/Year)

08/24/2015

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

☒ Director ☒ 10% Owner  
☐ Officer (give title below) ☐ Other (specify below)

6. Individual or Joint/Group Filing(Check  
Applicable Line)

☐ Form filed by One Reporting Person  
☒ Form filed by More than One Reporting  
Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of<br>Security<br>(Instr. 3) | 2. Transaction Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 3.<br>Transaction<br>Code<br>(Instr. 8) | 4. Securities Acquired<br>or Disposed of (D)<br>(Instr. 3, 4 and 5) | 5. Amount of<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 3 and 4) | 6.<br>Ownership<br>Form: Direct<br>(D) or<br>Indirect (I)<br>(Instr. 4) | 7. Nature of<br>Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---------------------------------------|-----------------------------------------|-------------------------------------------------------------|-----------------------------------------|---------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------|
|                                       |                                         |                                                             |                                         | (A)<br>or<br>(D)<br>Code V Amount (D) Price<br>\$                   |                                                                                                                    |                                                                         |                                                                   |
| Common<br>Stock                       | 08/21/2015                              |                                                             | P                                       | 397,900                                                             | A 1.82 632,907<br>(1)                                                                                              | I                                                                       | See<br>Footnotes<br>(2) (3) (4) (5)                               |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of  
information contained in this form are not  
required to respond unless the form  
displays a currently valid OMB control  
number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

# Edgar Filing: BioScrip, Inc. - Form 4/A

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2. Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 4. Transaction<br>Code<br>(Instr. 8) | 5. Number<br>of<br>Derivative<br>Securities<br>Acquired<br>(A) or<br>Disposed<br>of (D)<br>(Instr. 3,<br>4, and 5) | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) | 7. Title and<br>Amount of<br>Underlying<br>Securities<br>(Instr. 3 and 4) | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Nu<br>Deriv<br>Secur<br>Bene<br>Own<br>Follo<br>Repor<br>Trans<br>(Instr |
|-----------------------------------------------------|--------------------------------------------------------------------|-----------------------------------------|-------------------------------------------------------------|--------------------------------------|--------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|---------------------------------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------------------------------|
|                                                     |                                                                    |                                         |                                                             | Code                                 | V (A) (D)                                                                                                          | Date<br>Exercisable                                            | Expiration<br>Date                                                        | Title                                               | Amount<br>or<br>Number<br>of<br>Shares                                      |

## Reporting Owners

| Reporting Owner Name / Address                                                                             | Relationships |           |         |       |
|------------------------------------------------------------------------------------------------------------|---------------|-----------|---------|-------|
|                                                                                                            | Director      | 10% Owner | Officer | Other |
| Coliseum Capital Management, LLC<br>METRO CENTER<br>1 STATION PLACE, 7TH FLOOR SOUTH<br>STAMFORD, CT 06902 | X             | X         |         |       |
| Shackelton Christopher S<br>METRO CENTER<br>1 STATION PLACE, 7TH FLOOR,<br>STAMFORD, CT 06902              | X             | X         |         |       |
| Coliseum Capital, LLC<br>METRO CENTER<br>1 STATION PLACE, 7TH FLOOR,<br>STAMFORD, CT 06902                 | X             | X         |         |       |
| COLISEUM CAPITAL PARTNERS L P<br>METRO CENTER<br>1 STATION PLACE, 7TH FLOOR,<br>STAMFORD, CT 06902         | X             | X         |         |       |
| Coliseum Capital Partners II, L.P.<br>METRO CENTER<br>1 STATION PLACE, 7TH FLOOR,<br>STAMFORD, CT 06902    | X             | X         |         |       |
| Gray Adam<br>METRO CENTER<br>1 STATION PLACE, 7TH FLOOR,<br>STAMFORD, CT 06902                             | X             | X         |         |       |

## Signatures

|                                                                                                                             |            |
|-----------------------------------------------------------------------------------------------------------------------------|------------|
| Coliseum Capital Management, LLC, By: /s/ Christopher Shackelton, Manager                                                   | 08/26/2015 |
| __Signature of Reporting Person                                                                                             | Date       |
| /s/ Christopher Shackelton                                                                                                  | 08/26/2015 |
| __Signature of Reporting Person                                                                                             | Date       |
| Coliseum Capital, LLC, By: /s/ Christopher Shackelton, Manager                                                              | 08/26/2015 |
| __Signature of Reporting Person                                                                                             | Date       |
| Coliseum Capital Partners, L.P., By: Coliseum Capital, LLC, its General Partner, By: /s/ Christopher Shackelton, Manager    | 08/26/2015 |
| __Signature of Reporting Person                                                                                             | Date       |
| Coliseum Capital Partners II, L.P., By: Coliseum Capital, LLC, its General Partner, By: /s/ Christopher Shackelton, Manager | 08/26/2015 |
| __Signature of Reporting Person                                                                                             | Date       |
| Adam Gray, By: /s/ Christopher Shackelton, Attorney-in-fact                                                                 | 08/26/2015 |
| __Signature of Reporting Person                                                                                             | Date       |

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$1.76 to \$1.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- (2) These securities are held directly by (a) Coliseum Capital Partners, L.P. ("CCP"), an investment limited partnership of which Coliseum Capital, LLC, a Delaware limited liability company ("CC"), is general partner and for which Coliseum Capital Management, LLC, a Delaware limited liability company ("CCM"), serves as investment adviser, (b) Coliseum Capital Partners II, L.P. ("CCP2" and, together with CCP, the "Funds"), an investment limited partnership of which CC is general partner and for which CCM serves as investment adviser, and (c) a separate account investment advisory client of CCM (the "Separate Account").
- (3) Christopher Shackelton ("Shackelton") and Adam Gray ("Gray") are managers of and have an ownership interest in each of CCM and CC and may be deemed to have an indirect pecuniary interest in the shares held by the Funds and the Separate Account due to CCM's right to receive performance-related fees from the Separate Account and CC's right to receive performance-related fees from the Funds. Each of Shackelton, Gray, CCP, CCP2, the Separate Account, CC and CCM disclaims beneficial ownership of these securities except to the extent of that person's pecuniary interest therein.
- (4) Following the transactions reported herein, CCP, CCP2 and the Separate Account directly owned 380,186, 98,739 and 153,982 shares of common stock, respectively.
- (5) The transaction is not new, but is being reported again to gain access to the system. The amount of shares of common stock directly owned by CCP, CCP2 and the Separate Account following the transactions reported on August 24, 2015 was originally reported as 380,186, 119,364 and 133,357 shares, respectively. This amendment to Form 4 reflects the correct amount of shares of common stock directly owned by CCP, CCP2 and the Separate Account following the transactions reported on August 24, 2015 as 380,186, 98,739 and 153,982 shares, respectively.

### Remarks:

Shackelton is a director of the Issuer. As a result, the following persons may be deemed directors by deputization of the Issuer

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.